WO1982001649A1 - Nouvelle forme galenique du fenofibrate, son procede d'obtention, son application comme medicament - Google Patents
Nouvelle forme galenique du fenofibrate, son procede d'obtention, son application comme medicament Download PDFInfo
- Publication number
- WO1982001649A1 WO1982001649A1 PCT/FR1981/000148 FR8100148W WO8201649A1 WO 1982001649 A1 WO1982001649 A1 WO 1982001649A1 FR 8100148 W FR8100148 W FR 8100148W WO 8201649 A1 WO8201649 A1 WO 8201649A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fenofibrate
- granules
- new
- derivatives
- polymer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
Definitions
- New dosage form of fenofibrate its process of obtaining, its application as medicine.
- the present invention relates to a new galenical form of fenofibrate (DCI) and / or its derivatives, its production process and the medicaments comprising this form.
- DCI fenofibrate
- fenofibrate is isopropyl para- (4-chlorobenzoyl) -phenoxyisobutyrate.
- the expression “fenofibrate and its derivatives” denotes the compounds of formula I
- R 1 represents a phenyl group or a phenyl group substituted by one or more - CH 3 , CF 3 or halogens (in particular fluorine, chlorine or bromine),
- R 2 and R 3 independently represent a hydrogen or halogen atom (preferably fluorine, chlorine or bromine), an alkyl or alkoxy group having 1 to 5 C or a -CF 3 group,
- Y represents a group -OH, a lower alkoxy group, preferably C 1 - C 4 , a group -NR 4 R 5 , a group 4 -ement -NHCH 2 CH 2 NR 4 R 5 or a group -O-alkylene- NR 4 R 5 , the alkylene having in particular 2 to 6 carbon atoms R 4 and R 5 identical or different, each representing a hydrogen atom, a C 1 -C 5 alkyl group, a C 3 cycloalkyy group - C 7 , preferably in C 5 - C 6 an aryl or aryl group substituted on the aromatic residue by one or more halogen groups, methyl or -CF 3 , or else R 4 and R 5 form together with the nitrogen atom to which they are linked, either an n-heterocyclic group having 5 to 7 vertices which may contain a second heteroatom chosen from N, O and S, and which may be substituted, or an amide residue derived from Ivsine
- fenofibrate is used for the treatment of hyperlipidénaies, hypercholesterolimies and endogenous hypertrigiycéridémies of the adult.
- fenofibrate at a rate of 300 to 400 mg per day, a reduction of the cholera steremia of 20 to 25% and a reduction of the triglyceridemia of 40 to 50% . This significant action manifests itself from the first month of treatment and persists after 30 months of treatment.
- hyperiipidemias contribute to the increase in the statistical risk of vascular accident in particular coronary artery.
- the treatment of hyperipidemia with fenofibrate constitutes a long-term symptomatic treatment which is not without risks.
- fenofibrate is presented in the form of capsules dosed with 100 mg of active principle: the average daily dosage is 300 to 400 mg, sometimes 600 mg.
- the subject of the present invention is a new galenical form making it possible to reduce the dosage and the number of administrations thanks to the progressive and delayed release of fenofibrate and / or its derivatives.
- This form is remarkable in that it consists of granules comprising a neutral core consisting of a grit of an inert excipient comprising at least one constituent chosen from sucrose and lactose, optionally in mixture with starch, said neutral core being coated with a first layer containing fenofibrate and / or its derivatives in admixture with an excipient for the first layer comprising at least a first constituent chosen from talc, silica and their mixtures, and a second constituent which is stearic acid, then a second layer, or outer layer constituted by a microporous envelope comprising at least one polymer compatible with oral administration.
- the neutral core consists of sucrose, lactose or their mixtures.
- the neutral core can be a mixture comprising from 20 to 60% by weight of sucrose and / or lactose and from 1 to 40% by weight of starch. These proportions are expressed relative to the total weight of the new dosage form.
- the new dosage form contains from 0.01 to 1% approximately, and in particular from 0.1 to 0.5% by weight, of stearic acid, from 5 to 15% by weight. weight of talc and 2 to 10% by weight of drying silica.
- the neutral core can comprise fenibrate adsorbates and / or its derivatives.
- the new dosage form as defined above contains, relative to its total weight, from 25 to 55% approximately by weight of fenofibrate and / or its derivatives, and from 2 to 10% approximately by weight of polymer constituting the layer external, the rest being constituted by the other inert excipients, present for example in a proportion of 40 to 70% approximately.
- the neutral core generally represents 15 to 60%.
- the grain constituting the neutral core has dimensions of the order of 0.1 to 0.5 mm, and the granules, object of the invention, have dimensions not exceeding approximately 2 mm, these dimensions varying for example from 1 mm to 2 mm in most cases.
- the first layer can itself be composed of several sublayers (generally not more than 4) obtained by successive applications of fenofibrate and / or of its derivatives and of or excipients for said first layer.
- the invention is not limited to granules having determined proportions of polymer or a determined number of said sublayers, because one of the advantages of the new form of the invention is to produce a drug having a delayed effect controlled by the mixture of granules having different release rates of fenofibrate and / or its derivatives.
- the subject of the invention is also a process for obtaining the new galenical form which is remarkable in that the neutral granules are prepared beforehand by granulation, that they are dried and sieved, that these granules are impregnated with a solution of fenofibrate and / or its derivatives, which is then coated with said granules with said excipient for the first layer, which is repeated, if desired, the operations of impregnating fenofibrate and coating, then forming the microporeus ⁇ envelope by coating with said polymer in solution in a solvent.
- a pharmaceutically acceptable organic solvent is used in particular, such as ethane or acetone.
- the present invention relates to medicaments comprising the new form of administration of fenofibrate and / or its derivatives, in the form of active granules optionally mixed with neutral granules not coated with polymer in order to obtain a predetermined concentration in fenofibrate and / or its derivatives, this set of granules being presented in the form of capsules, tablets, suppositories, syrup, granules or powder.
- the corn starch and the sucrose are mixed and granulated, then the grains are sieved and blended for a long time so as to make them perfectly spherical. We sift again and dry perfectly.
- an alcoholic solution of fenofibrate is sprayed onto the neutral cores thus obtained.
- the first layer is then made by incorporating into these granules a part of the mixture of the other excipients (with the exception of shellac) then the spraying of fenofibrate is started again, this coating being repeated several times with sieving and drying if necessary between each undercoat.
- the microporous outer layer is produced, by spraying the shellac granules with gum shellac in solution in absolute ethyl alcohol, in an amount sufficient to impregnate all of the granules. It is then carefully dried, eliminating the ethyl alcohol remaining, it is again sieved and the title of the granules obtained is checked as below before putting into capsules, after having optionally adjusted the titration by addition and homogenized with neutral granules to arrive at the desired titration.
- granules according to the invention were prepared by replacing the shellac with polyvinylpyroli dane or with a polymethacrylate.
- Granules according to the invention have also been prepared in which the neutral core is exclusively made up of sucrose or lactose. Measurement of Fenofibrate Release
- a disintegration device in which a quantity of granules corresponding to approximately 250 mg of active principle is brought into contact with artificial liquids, the device making it possible to maintain constant agitation and a constant temperature of 37 ° ⁇ 0.5 ° C.
- Artificial liquids are solutions buffered at successive pH used according to the scheme below. Period Solutions TTeemmppss ddee pH% of principal active release
- the new dosage form leads to a new, remarkable drug, which is easier to use and whose side effects linked to its use are reduced.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL8120434A NL8120434A (nl) | 1980-11-19 | 1981-11-18 | Nieuwe galenische vorm van fenofibraat, werkwijze ter bereiding alsmede de geneeskundige toepassing daarvan. |
DE19813152519 DE3152519C2 (de) | 1980-11-19 | 1981-11-18 | Neues Fenofibrat-Fertigpr{parat mit verz¦gerter Wirkstofffreisetzung |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8024568A FR2494112B1 (fr) | 1980-11-19 | 1980-11-19 | |
FR8024568801119 | 1980-11-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1982001649A1 true WO1982001649A1 (fr) | 1982-05-27 |
Family
ID=9248140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1981/000148 WO1982001649A1 (fr) | 1980-11-19 | 1981-11-18 | Nouvelle forme galenique du fenofibrate, son procede d'obtention, son application comme medicament |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0065531A1 (fr) |
AT (1) | AT387517B (fr) |
BE (1) | BE891129A (fr) |
DE (1) | DE3152519C2 (fr) |
FR (1) | FR2494112B1 (fr) |
IT (1) | IT1144948B (fr) |
NL (1) | NL8120434A (fr) |
WO (1) | WO1982001649A1 (fr) |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2554718A1 (fr) * | 1983-11-14 | 1985-05-17 | Ethypharm Sa | Nouvelles formes galeniques du sulpiride utilisables par voie orale |
FR2556964A1 (fr) * | 1983-12-23 | 1985-06-28 | Ile De France | Nouvelles formes galeniques du sulpiride utilisables par voie orale |
EP0159891A1 (fr) * | 1984-04-18 | 1985-10-30 | Morinaga Milk Industry Co., Ltd. | Granulé formé de cellules séchées de micro-organismes et méthode de fabrication de ce granulé |
EP0168360A2 (fr) * | 1984-06-29 | 1986-01-15 | Roberto Valducci | Procédé pour la préparation de microgranules à effet retard contenant de l'étofibrate ou des composés similaires et produits ainsi obtenus |
FR2602423A1 (fr) * | 1986-08-08 | 1988-02-12 | Ethypharm Sa | Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede |
EP0330532A1 (fr) * | 1988-02-26 | 1989-08-30 | Fournier Industrie Et Sante | Nouvelle forme galénique du fénofibrate |
FR2737121A1 (fr) * | 1995-07-27 | 1997-01-31 | Cl Pharma | Nouvelles formulations galeniques du fenofibrate et leurs applications |
WO1998031360A1 (fr) * | 1997-01-17 | 1998-07-23 | Pharma Pass | Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation |
WO1998031361A1 (fr) * | 1997-01-17 | 1998-07-23 | Laboratoires Fournier S.A. | Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation |
US6180138B1 (en) | 1999-01-29 | 2001-01-30 | Abbott Laboratories | Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption |
US6368622B2 (en) | 1999-01-29 | 2002-04-09 | Abbott Laboratories | Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption |
US6372251B2 (en) | 1999-06-11 | 2002-04-16 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
US6383517B1 (en) | 1999-01-29 | 2002-05-07 | Abbott Laboratories | Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption |
US6465011B2 (en) | 1999-05-29 | 2002-10-15 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
US6511985B1 (en) | 1998-12-18 | 2003-01-28 | Bayer Aktiengesellschaft | Combination of cerivastatin and fibrates |
US6531158B1 (en) | 2000-08-09 | 2003-03-11 | Impax Laboratories, Inc. | Drug delivery system for enhanced bioavailability of hydrophobic active ingredients |
US6719999B2 (en) | 1999-03-31 | 2004-04-13 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
US6814977B1 (en) | 1998-12-18 | 2004-11-09 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
US6838091B2 (en) | 1998-12-18 | 2005-01-04 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
WO2005002541A2 (fr) * | 2003-07-02 | 2005-01-13 | Abbott Laboratories | Procede de preparation de produits formules de medicaments de regulation du metabolisme lipidique |
US6982281B1 (en) | 2000-11-17 | 2006-01-03 | Lipocine Inc | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
US7014864B1 (en) | 1998-12-18 | 2006-03-21 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
US7101574B1 (en) | 1999-07-09 | 2006-09-05 | Laboratoires Des Produits Ethiques Ethypharm | Pharmaceutical composition containing fenofibrate and the preparation method |
EP1785133A1 (fr) | 2005-11-10 | 2007-05-16 | Laboratoires Fournier S.A. | Utilisation du fenofibrate ou d'un de ses dérivés pour la prevention de la retinopathie diabetique |
US7863331B2 (en) | 1999-07-09 | 2011-01-04 | Ethypharm | Pharmaceutical composition containing fenofibrate and method for the preparation thereof |
US8062664B2 (en) | 2003-11-12 | 2011-11-22 | Abbott Laboratories | Process for preparing formulations of lipid-regulating drugs |
US8865695B2 (en) | 2009-01-08 | 2014-10-21 | Lipocine Inc. | Steroidal compositions |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
US10561615B2 (en) | 2010-12-10 | 2020-02-18 | Lipocine Inc. | Testosterone undecanoate compositions |
US11433083B2 (en) | 2010-11-30 | 2022-09-06 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US11559530B2 (en) | 2016-11-28 | 2023-01-24 | Lipocine Inc. | Oral testosterone undecanoate therapy |
US11707467B2 (en) | 2014-08-28 | 2023-07-25 | Lipocine Inc. | (17-ß)-3-oxoandrost-4-en-17YL tridecanoate compositions and methods of their preparation and use |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19608750A1 (de) * | 1996-03-06 | 1997-09-11 | Durachemie Gmbh & Co Kg | Verfahren zur Herstellung von Fenofibrat-Präparaten |
FR2819720B1 (fr) | 2001-01-22 | 2004-03-12 | Fournier Lab Sa | Nouveaux comprimes de fenofibrate |
WO2004028506A1 (fr) * | 2002-09-24 | 2004-04-08 | Ranbaxy Laboratories Limited | Compositions pharmaceutiques de fenofibrate par voie orale a biodisponibilite elevee |
CA2505521A1 (fr) * | 2002-11-22 | 2004-06-10 | Meiji Seika Kaisha, Ltd. | Composition granulaire et son procede de production |
JP2006511541A (ja) * | 2002-12-17 | 2006-04-06 | アボット ゲーエムベーハー ウント カンパニー カーゲー | フェノフィブル酸、その生理学的に許容し得る塩または誘導体を含有してなる製剤 |
EP1829541A1 (fr) * | 2002-12-17 | 2007-09-05 | Abbott GmbH & Co. KG | Formulation comprenant de l'acide fénofibrique ou l'un de ses sels physiologiquement acceptable |
WO2008075320A2 (fr) * | 2006-12-21 | 2008-06-26 | Ranbaxy Laboratories Limited | Compositions pharmaceutiques antilipidémiques et leur procédé de préparation |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2963402A (en) * | 1955-01-18 | 1960-12-06 | Nysco Lab Inc | Sustained release medicament |
FR1347413A (fr) * | 1963-01-29 | 1963-12-27 | Italnysco S P A | Sphérules ou globules à action étalée et procédé pour leur préparation |
FR2157853A2 (fr) * | 1971-10-14 | 1973-06-08 | Fournier Gmbh Lab | |
FR2313915A1 (fr) * | 1976-01-26 | 1977-01-07 | Corneille Gilbert | Nouvelle forme galenique d'administration de la vincamine et de ses derives, son procede de preparation et medicaments comprenant cette nouvelle forme |
FR2390959A1 (fr) * | 1977-05-16 | 1978-12-15 | Prugnaud Robert | Association therapeutique a visee anti-agregante et regularisatrice de la duree de vie plaquettaire a base de pyrimido-pyrimidine et d'acide acetyl salycilique |
FR2432313A1 (fr) * | 1978-08-01 | 1980-02-29 | Foulhoux Pierre | Nouvelle forme galenique de la betahistine et son procede d'obtention |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773920A (en) * | 1971-07-14 | 1973-11-20 | Nikken Chemicals Co Ltd | Sustained release medicinal composition |
DE2336218C3 (de) * | 1973-07-17 | 1985-11-14 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Orale Arzneiform |
ZA765931B (en) * | 1975-10-10 | 1977-09-28 | Squibb & Sons Inc | Controlled release tablet |
-
1980
- 1980-11-19 FR FR8024568A patent/FR2494112B1/fr not_active Expired
-
1981
- 1981-11-16 BE BE1/10357A patent/BE891129A/fr not_active IP Right Cessation
- 1981-11-18 AT AT0906481A patent/AT387517B/de not_active IP Right Cessation
- 1981-11-18 DE DE19813152519 patent/DE3152519C2/de not_active Expired - Lifetime
- 1981-11-18 WO PCT/FR1981/000148 patent/WO1982001649A1/fr active Application Filing
- 1981-11-18 NL NL8120434A patent/NL8120434A/nl unknown
- 1981-11-18 EP EP81903096A patent/EP0065531A1/fr not_active Withdrawn
- 1981-11-19 IT IT25185/81A patent/IT1144948B/it active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2963402A (en) * | 1955-01-18 | 1960-12-06 | Nysco Lab Inc | Sustained release medicament |
FR1347413A (fr) * | 1963-01-29 | 1963-12-27 | Italnysco S P A | Sphérules ou globules à action étalée et procédé pour leur préparation |
FR2157853A2 (fr) * | 1971-10-14 | 1973-06-08 | Fournier Gmbh Lab | |
FR2313915A1 (fr) * | 1976-01-26 | 1977-01-07 | Corneille Gilbert | Nouvelle forme galenique d'administration de la vincamine et de ses derives, son procede de preparation et medicaments comprenant cette nouvelle forme |
FR2390959A1 (fr) * | 1977-05-16 | 1978-12-15 | Prugnaud Robert | Association therapeutique a visee anti-agregante et regularisatrice de la duree de vie plaquettaire a base de pyrimido-pyrimidine et d'acide acetyl salycilique |
FR2432313A1 (fr) * | 1978-08-01 | 1980-02-29 | Foulhoux Pierre | Nouvelle forme galenique de la betahistine et son procede d'obtention |
Non-Patent Citations (1)
Title |
---|
Arzneimittel-Forschung, Vol. 26, No. 5, 1976, Editio Cantor (Aulendorf, DE) R.R. BRODIE et al.: "Antilipidemic Drugs", pages 896-901, see page 897, left-hand column, "3.3. Studies with Man", paragraph 2 * |
Cited By (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2554718A1 (fr) * | 1983-11-14 | 1985-05-17 | Ethypharm Sa | Nouvelles formes galeniques du sulpiride utilisables par voie orale |
WO1985002114A1 (fr) * | 1983-11-14 | 1985-05-23 | Societe Anonyme Ethypharm | Nouvelles formes galeniques du sulpiride utlisables par voie orale |
EP0145558A2 (fr) * | 1983-11-14 | 1985-06-19 | Societe D'etudes Scientifiques Et Industrielles De L'ile-De-France | Nouvelles formes galéniques du sulpiride utilisables par voie orale |
EP0145558A3 (en) * | 1983-11-14 | 1985-08-07 | Ethypharm, Societe Anonyme | Galenic forms of sulpiride for oral administration |
FR2556964A1 (fr) * | 1983-12-23 | 1985-06-28 | Ile De France | Nouvelles formes galeniques du sulpiride utilisables par voie orale |
EP0147244A1 (fr) * | 1983-12-23 | 1985-07-03 | Societe D'etudes Scientifiques Et Industrielles De L'ile-De-France | Nouvelles formes galéniques du sulpiride utilisables par voie orale |
DE3412868A1 (de) * | 1983-12-23 | 1985-07-11 | Ile De France | Neue galenische formen fuer sulpirid |
GB2151920A (en) * | 1983-12-23 | 1985-07-31 | Ile De France | Oral compositions containing sulpiride |
EP0159891A1 (fr) * | 1984-04-18 | 1985-10-30 | Morinaga Milk Industry Co., Ltd. | Granulé formé de cellules séchées de micro-organismes et méthode de fabrication de ce granulé |
EP0168360A2 (fr) * | 1984-06-29 | 1986-01-15 | Roberto Valducci | Procédé pour la préparation de microgranules à effet retard contenant de l'étofibrate ou des composés similaires et produits ainsi obtenus |
EP0168360A3 (en) * | 1984-06-29 | 1987-01-07 | Roberto Valducci | Process for preparing etofibrate or similar compounds containing sustained release microgranules and products thus obtained |
FR2602423A1 (fr) * | 1986-08-08 | 1988-02-12 | Ethypharm Sa | Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede |
EP0256933A1 (fr) * | 1986-08-08 | 1988-02-24 | Ethypharm | Procédé de préparation d'un médicament à base de fénofibrate, médicament obtenu par ce procédé |
AU601462B2 (en) * | 1986-08-08 | 1990-09-13 | Ethypharm | A medicine based on fenofibrate, and a method of preparing it |
EP0330532A1 (fr) * | 1988-02-26 | 1989-08-30 | Fournier Industrie Et Sante | Nouvelle forme galénique du fénofibrate |
FR2627696A1 (fr) * | 1988-02-26 | 1989-09-01 | Fournier Innovation Synergie | Nouvelle forme galenique du fenofibrate |
US4895726A (en) * | 1988-02-26 | 1990-01-23 | Fournier Innovation Et Synergie | Novel dosage form of fenofibrate |
EP0757911A1 (fr) * | 1995-07-27 | 1997-02-12 | Cll Pharma | Nouvelles formulations galéniques du fénofibrate et leurs applications |
FR2737121A1 (fr) * | 1995-07-27 | 1997-01-31 | Cl Pharma | Nouvelles formulations galeniques du fenofibrate et leurs applications |
US5827536A (en) * | 1995-07-27 | 1998-10-27 | Cll Pharma | Pharmaceutical dosage formulations of fenofibrate and their applications |
FR2758459A1 (fr) * | 1997-01-17 | 1998-07-24 | Pharma Pass | Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation |
EP1273294A1 (fr) * | 1997-01-17 | 2003-01-08 | Laboratoires Fournier S.A. | Composition pharmaceutique de fénofibrate présentant une biodisponibilité élévée et son procédé de préparation |
FR2758461A1 (fr) * | 1997-01-17 | 1998-07-24 | Pharma Pass | Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation |
EP1468681A1 (fr) * | 1997-01-17 | 2004-10-20 | Laboratoires Fournier S.A. | Composition pharmaceutique de fénofibrate présentant une biodisponibilité élevée |
AU731964B2 (en) * | 1997-01-17 | 2001-04-05 | Bgp Products Operations Gmbh | Pharmaceutical composition of fenofibrate with high biological availability and method for preparing same |
US8329214B2 (en) | 1997-01-17 | 2012-12-11 | Laboratoires Fournier S.A. | Process for producing fenofibrate tablets |
CN1496738B (zh) * | 1997-01-17 | 2011-03-30 | 福赫尼实验室股份有限公司 | 具有高生物利用率的非诺贝特药物组合物及其制备方法 |
CZ297251B6 (cs) * | 1997-01-17 | 2006-10-11 | Laboratoires Fournier S. A. | Fenofibrátový prostredek s okamzitým uvolnováním,zpusob prípravy farmaceutického prostredku a suspenze fenofibrátu v mikronizované forme |
US7041319B2 (en) | 1997-01-17 | 2006-05-09 | Laboratoires Fournier | Fenofibrate pharmaceutical composition having high bioavailabilty |
WO1998031361A1 (fr) * | 1997-01-17 | 1998-07-23 | Laboratoires Fournier S.A. | Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation |
EP1273293A1 (fr) * | 1997-01-17 | 2003-01-08 | Laboratoires Fournier S.A. | Suspension de fénofibrate dans une solution de polymère hydrophile |
EP1275387A1 (fr) * | 1997-01-17 | 2003-01-15 | Laboratoires Fournier S.A. | Composition pharmaceutique de fénofibrate présentant une biodisponibilité élévée et son procédé de préparation |
US7037529B2 (en) | 1997-01-17 | 2006-05-02 | Laboratoires Fournier | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it |
WO1998031360A1 (fr) * | 1997-01-17 | 1998-07-23 | Pharma Pass | Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation |
US8343540B2 (en) | 1997-01-17 | 2013-01-01 | Laboratories Fournier S.A. | Process for producing fenofibrate tablets |
US6589552B2 (en) | 1997-01-17 | 2003-07-08 | Laboratoires Fournier, S.A. | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it |
US6596317B2 (en) | 1997-01-17 | 2003-07-22 | Laboratoires Fournier, Sa | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it |
US6652881B2 (en) | 1997-01-17 | 2003-11-25 | Laboratories Fournier, S.A. | Fenofibrate pharmaceutical composition having high bioavailability |
US6814977B1 (en) | 1998-12-18 | 2004-11-09 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
US6838091B2 (en) | 1998-12-18 | 2005-01-04 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
US7014864B1 (en) | 1998-12-18 | 2006-03-21 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
US6511985B1 (en) | 1998-12-18 | 2003-01-28 | Bayer Aktiengesellschaft | Combination of cerivastatin and fibrates |
US6383517B1 (en) | 1999-01-29 | 2002-05-07 | Abbott Laboratories | Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption |
US6180138B1 (en) | 1999-01-29 | 2001-01-30 | Abbott Laboratories | Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption |
US6368622B2 (en) | 1999-01-29 | 2002-04-09 | Abbott Laboratories | Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption |
US6719999B2 (en) | 1999-03-31 | 2004-04-13 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
US6465011B2 (en) | 1999-05-29 | 2002-10-15 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
US6372251B2 (en) | 1999-06-11 | 2002-04-16 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
US8658212B2 (en) | 1999-07-09 | 2014-02-25 | Ethypharm | Pharmaceutical composition containing fenofibrate and method for the preparation thereof |
US7101574B1 (en) | 1999-07-09 | 2006-09-05 | Laboratoires Des Produits Ethiques Ethypharm | Pharmaceutical composition containing fenofibrate and the preparation method |
US8563042B2 (en) | 1999-07-09 | 2013-10-22 | Ethypharm | Pharmaceutical composition containing fenofibrate and method for the preparation thereof |
US7863331B2 (en) | 1999-07-09 | 2011-01-04 | Ethypharm | Pharmaceutical composition containing fenofibrate and method for the preparation thereof |
US8529952B2 (en) | 1999-07-09 | 2013-09-10 | Ethypharm | Pharmaceutical composition containing fenofibrate and method for the preparation thereof |
US6531158B1 (en) | 2000-08-09 | 2003-03-11 | Impax Laboratories, Inc. | Drug delivery system for enhanced bioavailability of hydrophobic active ingredients |
US6982281B1 (en) | 2000-11-17 | 2006-01-03 | Lipocine Inc | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
WO2005002541A2 (fr) * | 2003-07-02 | 2005-01-13 | Abbott Laboratories | Procede de preparation de produits formules de medicaments de regulation du metabolisme lipidique |
WO2005002541A3 (fr) * | 2003-07-02 | 2005-09-15 | Abbott Lab | Procede de preparation de produits formules de medicaments de regulation du metabolisme lipidique |
US8062664B2 (en) | 2003-11-12 | 2011-11-22 | Abbott Laboratories | Process for preparing formulations of lipid-regulating drugs |
EP3167882A1 (fr) | 2005-11-10 | 2017-05-17 | BGP Products Operations GmbH | Utilisation de fénofibrate ou d'un de ses dérivés pour la prévention de la rétinopathie diabétique |
EP1785133A1 (fr) | 2005-11-10 | 2007-05-16 | Laboratoires Fournier S.A. | Utilisation du fenofibrate ou d'un de ses dérivés pour la prevention de la retinopathie diabetique |
US8865695B2 (en) | 2009-01-08 | 2014-10-21 | Lipocine Inc. | Steroidal compositions |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
US11052096B2 (en) | 2009-01-08 | 2021-07-06 | Lipocine Inc. | Steroidal compositions |
US10226473B2 (en) | 2010-11-30 | 2019-03-12 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US10881671B2 (en) | 2010-11-30 | 2021-01-05 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9480690B2 (en) | 2010-11-30 | 2016-11-01 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9757390B2 (en) | 2010-11-30 | 2017-09-12 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US11433083B2 (en) | 2010-11-30 | 2022-09-06 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9943527B2 (en) | 2010-11-30 | 2018-04-17 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9949985B2 (en) | 2010-11-30 | 2018-04-24 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US11364249B2 (en) | 2010-11-30 | 2022-06-21 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US10716794B2 (en) | 2010-11-30 | 2020-07-21 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US10799513B2 (en) | 2010-11-30 | 2020-10-13 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US11364250B2 (en) | 2010-11-30 | 2022-06-21 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US10973833B2 (en) | 2010-11-30 | 2021-04-13 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9205057B2 (en) | 2010-11-30 | 2015-12-08 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US11311555B2 (en) | 2010-11-30 | 2022-04-26 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US10561615B2 (en) | 2010-12-10 | 2020-02-18 | Lipocine Inc. | Testosterone undecanoate compositions |
US11298365B2 (en) | 2014-08-28 | 2022-04-12 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
US9757389B2 (en) | 2014-08-28 | 2017-09-12 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
US11707467B2 (en) | 2014-08-28 | 2023-07-25 | Lipocine Inc. | (17-ß)-3-oxoandrost-4-en-17YL tridecanoate compositions and methods of their preparation and use |
US11872235B1 (en) | 2014-08-28 | 2024-01-16 | Lipocine Inc. | Bioavailable solid state (17-β)-Hydroxy-4-Androsten-3-one esters |
US11559530B2 (en) | 2016-11-28 | 2023-01-24 | Lipocine Inc. | Oral testosterone undecanoate therapy |
Also Published As
Publication number | Publication date |
---|---|
BE891129A (fr) | 1982-05-17 |
FR2494112A1 (fr) | 1982-05-21 |
AT387517B (de) | 1989-02-10 |
IT1144948B (it) | 1986-10-29 |
IT8125185A0 (it) | 1981-11-19 |
FR2494112B1 (fr) | 1986-01-10 |
EP0065531A1 (fr) | 1982-12-01 |
ATA906481A (de) | 1988-07-15 |
DE3152519T1 (de) | 1983-12-29 |
NL8120434A (nl) | 1982-10-01 |
DE3152519C2 (de) | 1990-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1982001649A1 (fr) | Nouvelle forme galenique du fenofibrate, son procede d'obtention, son application comme medicament | |
EP0256933B1 (fr) | Procédé de préparation d'un médicament à base de fénofibrate, médicament obtenu par ce procédé | |
EP0385846B1 (fr) | Composition pharmaceutique à libération prolongée d'acide valproîque | |
US4752470A (en) | Controlled release indomethacin | |
US5296232A (en) | Pharmaceutical formulation which does not induce tolerance | |
FR2547498A1 (fr) | Comprimes de naproxen et de naproxen sodique a liberation controlee | |
EP1178778B1 (fr) | Granules contenant une substance vegetale et leur procede de preparation | |
US4803080A (en) | Sustained-release theophylline formulation | |
EP0063132B1 (fr) | Nouvelle forme galenique d'administration du metoclopramide, son procede de preparation et medicament comprenant cette nouvelle forme | |
EP1054672B1 (fr) | Microgranules de sulfate de morphine, procede de fabrication et preparations pharmaceutiques | |
CH646604A5 (fr) | Composition pharmaceutique a effet prolonge et son procede de fabrication. | |
EP0107557A1 (fr) | Nouvelle forme galénique du sulpiride, son procédé de préparation et médicament comprenant cette nouvelle forme | |
WO2022200402A1 (fr) | Formulation par voie orale d'ivermectine et utilisations | |
EP0145558B1 (fr) | Nouvelles formes galéniques du sulpiride utilisables par voie orale | |
EP0483320B1 (fr) | Compositions pharmaceutiques du type a liberation prolongee destinees a l'administration par voie orale et leur procede de preparation | |
EP0147244A1 (fr) | Nouvelles formes galéniques du sulpiride utilisables par voie orale | |
JPS62240618A (ja) | 持続性製剤 | |
CA2190807C (fr) | Composition pharmaceutique stable a base d'acide acetylsalicylique et de tocopherol | |
EP0412877A1 (fr) | Nouvelle forme galénique orale améliorant la biodisponibilité | |
BE1000087A3 (fr) | Compositions pharmaceutiques contenant de la vinburnine et leur procede de preparation. | |
CA2595496A1 (fr) | Medicament destine a etre administre par voie orale comprenant un inhibiteur de la cyclo-oxygenase-2, et son procede de preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 1981 9064 Country of ref document: AT Date of ref document: 19820527 Kind code of ref document: A |
|
AK | Designated states |
Designated state(s): AT CH DE GB LU NL |
|
AL | Designated countries for regional patents |
Designated state(s): FR |
|
RET | De translation (de og part 6b) |
Ref document number: 3152519 Country of ref document: DE Date of ref document: 19831229 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3152519 Country of ref document: DE |